Sibelium: Targeted Migraine Prophylaxis for Lasting Relief
Sibelium
| Product dosage: 10 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.37 | $41.00 (0%) | 🛒 Add to cart |
| 60 | $0.75 | $82.00 $45.00 (45%) | 🛒 Add to cart |
| 90 | $0.56 | $123.00 $50.00 (59%) | 🛒 Add to cart |
| 120 | $0.44 | $164.00 $53.00 (68%) | 🛒 Add to cart |
| 180 | $0.31
Best per tab | $246.00 $55.00 (78%) | 🛒 Add to cart |
| Product dosage: 5 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $1.20 | $36.00 (0%) | 🛒 Add to cart |
| 60 | $0.68 | $72.00 $41.00 (43%) | 🛒 Add to cart |
| 90 | $0.48 | $108.00 $43.00 (60%) | 🛒 Add to cart |
| 120 | $0.39 | $144.00 $47.00 (67%) | 🛒 Add to cart |
| 180 | $0.27
Best per tab | $216.00 $49.00 (77%) | 🛒 Add to cart |
Synonyms | |||
Sibelium, with the active ingredient flunarizine dihydrochloride, is a calcium channel blocker specifically indicated for the prophylactic management of migraine. It represents a cornerstone in preventive neurological therapy, designed to reduce the frequency and severity of migraine attacks. By modulating vascular tone and neuronal calcium influx, it addresses the underlying pathophysiology of migraine, offering a strategic, long-term solution for patients debilitated by recurrent episodes. Its well-established efficacy profile makes it a first-line consideration for neurologists and headache specialists seeking to improve patient quality of life.
Features
- Active Ingredient: Flunarizine dihydrochloride 5mg or 10mg per tablet.
- Pharmacological Class: Selective calcium channel blocker with additional antihistaminic and dopaminergic properties.
- Mechanism of Action: Inhibits calcium influx into vascular smooth muscle cells and neurons, preventing cerebral vasospasm and stabilizing neuronal membranes.
- Presentation: Film-coated tablets for oral administration.
- Bioavailability: High oral bioavailability with extensive tissue distribution, including crossing the blood-brain barrier.
- Half-life: Exhibits a long elimination half-life (approximately 18 days), allowing for once-daily dosing and sustained therapeutic effect.
Benefits
- Significantly reduces the frequency, duration, and intensity of migraine attacks, leading to fewer days lost to debilitating pain.
- Decreases the reliance on acute migraine medications (analgesics, triptans), thereby reducing the risk of medication-overuse headache.
- Improves overall quality of life by allowing for better daily function, planning, and reduced anxiety about impending attacks.
- Offers a convenient once-daily dosing regimen, enhancing long-term treatment adherence.
- Provides a well-tolerated prophylactic option with a mechanism of action distinct from beta-blockers or antiepileptics.
Common use
Sibelium (flunarizine) is primarily prescribed for the prophylaxis of classic and common migraine. It is indicated for patients experiencing frequent and/or severe migraine attacks that significantly impair normal activities, typically defined as two or more debilitating attacks per month. It is not intended for the acute treatment of a migraine attack already in progress. Its use is also recognized in some regions for the management of vertigo of peripheral vestibular origin and other vascular disorders, though its primary and most evidence-supported application remains in migraine prevention.
Dosage and direction
The dosage must be individualized based on patient response and tolerance. Therapy is typically initiated at a low dose and may be titrated upwards.
- Adults (18-65 years): The recommended starting dose is 10 mg (two 5 mg tablets or one 10 mg tablet) taken orally once daily in the evening. For elderly patients or those of low body weight, a starting dose of 5 mg daily may be recommended.
- Maintenance: After one month, the dose may be reduced to 5 mg once daily for maintenance therapy. The minimal effective dose should be used.
- Elderly (>65 years): A starting dose of 5 mg daily is recommended. Dose adjustment should be made cautiously based on clinical response and tolerance.
- Pediatric Population: The safety and efficacy in children have not been fully established. Use is not generally recommended.
- Administration: The tablet should be swallowed whole with a glass of water, with or without food. Evening administration is preferred to mitigate potential sedative effects during the day.
Precautions
- Extrapyramidal Symptoms: Patients should be monitored for the emergence of parkinsonism or other extrapyramidal symptoms, particularly elderly patients. The drug should be discontinued if such symptoms appear.
- Depression: Caution is advised in patients with a history of depression or pre-existing depressive symptoms, as flunarizine can potentially exacerbate this condition.
- Weight Gain: Patients should be informed of the potential for weight gain and advised to monitor their weight and maintain a healthy diet and exercise regimen.
- Drowsiness/Sedation: Sibelium can cause drowsiness and somnolence, especially at the beginning of treatment. Patients should be cautioned against driving or operating machinery until they know how the medication affects them.
- Hepatic/Renal Impairment: Use with caution in patients with severe hepatic or renal impairment, as pharmacokinetics may be altered.
- Pregnancy and Lactation: The use of Sibelium during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus. It is not known if flunarizine is excreted in human milk; a decision should be made to discontinue nursing or discontinue the drug.
Contraindications
Sibelium is contraindicated in patients with:
- Known hypersensitivity to flunarizine dihydrochloride, other calcium channel blockers, or any of the excipients in the formulation.
- History of depressive illness, or currently presenting with symptoms of depression.
- Pre-existing extrapyramidal disorders, such as Parkinson’s disease.
- Severe hepatic impairment (e.g., Child-Pugh class C).
Possible side effect
Like all medicines, Sibelium can cause side effects, although not everybody gets them. Common side effects (may affect up to 1 in 10 people) include:
- Drowsiness, sedation, somnolence.
- Weight gain.
- Fatigue, asthenia.
- Dry mouth.
- Nausea.
Less common side effects (may affect up to 1 in 100 people) include:
- Depression, depressed mood.
- Extrapyramidal symptoms (e.g., muscle rigidity, tremor, akathisia).
- Galactorrhea (inappropriate milk secretion).
- Increased appetite.
- Skin reactions (e.g., rash).
- Bradycardia (slow heart rate).
- Gastrointestinal disturbances (e.g., stomach pain).
Rare side effects have also been reported. Patients should report any unusual or severe symptoms to their physician.
Drug interaction
Concurrent use of Sibelium with other agents requires careful monitoring due to potential pharmacodynamic interactions.
- CNS Depressants: Alcohol, barbiturates, opioids, benzodiazepines, sedating antihistamines, or other sedative drugs may potentiate the sedative effects of flunarizine.
- Antihypertensives: May have an additive effect in lowering blood pressure. Caution is advised with concomitant use of other vasodilators or antihypertensive drugs.
- Drugs that cause Extrapyramidal Symptoms: Concomitant use with antipsychotics (e.g., haloperidol) or metoclopramide may increase the risk of extrapyramidal side effects.
- Hepatic Enzyme Inhibitors/Inducers: As flunarizine is metabolized by the liver, drugs that inhibit (e.g., cimetidine, certain antifungals) or induce (e.g., rifampicin, carbamazepine) cytochrome P450 enzymes may alter its plasma concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to make up for a forgotten one.
Overdose
Symptoms of overdose are primarily an extension of the drug’s known pharmacological effects and may include severe drowsiness, sedation, coma, bradycardia, and hypotension. In case of suspected overdose, seek immediate medical attention. General supportive measures should be instituted, including gastric lavage if ingestion was recent. There is no specific antidote. Treatment should be symptomatic and supportive, with monitoring of vital signs and cardiac function. Hemodialysis is unlikely to be beneficial due to the drug’s high protein binding and large volume of distribution.
Storage
- Store below 30°C (86°F).
- Keep the blister strips in the outer carton to protect from light and moisture.
- Keep out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP.”.
- Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the typical properties of the drug and may not be fully comprehensive or reflect the most recent regulatory updates for your specific region.
Reviews
“After a decade of struggling with weekly migraines that triptans barely touched, my neurologist started me on Sibelium. The first month was tough with drowsiness, but we persisted. I’ve now been on a maintenance dose for six months and have had only two minor migraines. It’s been life-changing.” – Sarah K., 42
“As a physician, I find Sibelium to be a valuable tool in my arsenal for migraine prophylaxis, particularly in patients who cannot tolerate beta-blockers. The key is patient education about the potential for initial sedation and weight gain. When managed correctly, the long-term benefits for suitable candidates are significant.” – Dr. A. Evans, Neurologist
“The weight gain was a significant downside for me, about 8 kg over six months, even with careful dieting. While it did reduce my migraine frequency, the trade-off wasn’t sustainable for my personal well-being. We are now exploring alternative options.” – Mark T., 35